Sirturo- a diarylquinoline (bedaquiline): a novel approach for the treatment of MDR-TB and pre-XDR TB

Saraswathi Uradi

doi:10.18203/issn.2454-2156.IntJSciRep20232515

Authors

Saraswathi Uradi Department of Pharm D, Nova College of Pharmacy, Rangareddy, Telangana, India

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20232515

Keywords:

Bedaquiline, Mycobacterium TB, Anti-tubercular drugs, Multi-drug resistance, Diarylquinoline, Fluoroquinolones

Abstract

Sirturo (bedaquiline fumarate) is a new antitubercular class of medicine, lately, FDA, approved and indicated for use as a part of an appropriate applicable combination regimen along with other antitubercular medicines (i. e.; 2nd line anti-TB agents) for pulmonary multidrug-resistant tuberculosis (MDR TB) in grown up with age 12 years to less than 18 years of age and weighing at least 30 kg when an alternative treatment regimen cannot be considered for the reasons of resistance or tolerability. Bedaquiline, an enantiomer chemically belongs to the diarylquinoline (DAR) compound, which is nearly related to fluoroquinolones and chloroquine with differences in their side-chain moiety. Amongst all anti-TB medicines that have been approved, bedaquiline has a unique mechanism, which targets energy metabolism i. e.; adenosine triphosphate of mycobacteria, and eventually leads to bacterial cell lysis. ATP is an essential energy-producing molecule required for metabolic actions and survival of Mycobacteria and also for many other cells. Mycobacteria generally invade into well-encapsulated lung cavities and endosomes of macrophages, which can survive even under low oxygen levels leading to resistance against standard TB drugs. Bedaquiline has a spectrum of activity against drug-susceptible TB and MDR TB. Many clinical trials and studies demonstrated that bedaquiline is a crucial component of a combination regimen for multidrug-resistant TB.

Metrics

Metrics Loading ...

References

Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle. 1991;72(1):1-6.

Bloch AB, Rieder HL, Kelly GD, Cauthen GM, Hayden CH, Snider DE. The epidemiology of tuberculosis in the United States. Semin Respir Infect. 1989;4(3):157-70.

Styblo K. The global aspects of tuberculosis and HIV infection. Bull Int Union Tuberc Lung Dis. 1990;65(1):28-32.

Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)! Am Rev Respir Dis. 1991;143(4 Pt 1):697-8.

Murray CJL. Health priority review: tuberculosis. In: Dean T, eds. Disease control priorities in developing countries. New York: Oxford University Press; 1991.

Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380-7.

WHO. Global tuberculosis control a short update to the 2009 report, 2009. Available at: https://apps.who.int/iris/bitstream/handle/10665/44241/9789241598866. Accessed on 02 June 2023.

Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010;5(6):849-58.

WHO. ATC/DDD Index 2023, 2023. Available at: https://www.whocc.no/atc_ddd_index/. Accessed on 02 June 2023.

Lyons MA. Pharmacodynamics and Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2022;66(2):e0163621.

O'Neil M. The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry; 2013.

Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(8):2831-5.

EMA. Sirturo, 2023. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/sirturo. Accessed on 02 June 2023.

Drug bank. Bedaquiline, 2023. Available at: https://www.drugbank.ca/drugs/DB08903. Accessed on 02 June 2023.

Berney M, Cook GM. Unique flexibility in energy metabolism allows mycobacteria to combat starvation and hypoxia. PLoS One. 2010;5(1):e8614.

Tran SL, Cook GM. The F1Fo-ATP synthase of Mycobacterium smegmatis is essential for growth. J Bacteriol. 2005;187(14):5023-8.

Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007;51(11):4202-4.

Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol. 2007;3(6):323-4.

Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307(5707):223-7.

Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52(8):2831-5.

Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, et al. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother. 2012;56(3):1444-51.

Leibert E, Danckers M, Rom WN. New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag. 2014;10:597-602.

Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother. 2014;69(9):2310-8.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271-6.

Mesens N, Steemans M, Hansen E, Verheyen GR, Van Goethem F, Van Gompel J. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol In Vitro. 2010;24(5):1417-25.

Yao C, Guo H, Li Q, Zhang X, Shang Y, Li T, Wang Y, et al. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. Antimicrob Resist Infect Control. 2021;10(1):126.

US FDA. Sirturo (bedaquiline) label, 2012. Available at: https://www.accessdata.fda.gov/drugsatfda. Accessed on 02 June 2023.

Salinger DH, Nedelman JR, Mendel C, Spigelman M, Hermann DJ. Daily Dosing for Bedaquiline in Patients with Tuberculosis. Antimicrob Agents Chemother. 2019;63(11):e00463-19.

Nagabushan H, Roopadevi HS. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis. J Postgrad Med. 2014;60(3):300-2.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271-6.

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397-405.

Chan B, Khadem TM, Brown J. A review of tuberculosis: Focus on bedaquiline. Am J Health Syst Pharm. 2013;70(22):1984-94.

Republic of South Africa. Introduction of new drugs and drug regimens for the management of drugresistant tuberculosis in South Africa: policy framework, 2015. Available at: https://www.nicd.ac.za/assets/files/Introduction%20of%20new%. Accessed on 02 June 2023.

Everitt D, Winter H, Egizi E. Pharmacokinetic interaction between the investigational anti-tuberculosis agent TMC207 and rifampicin or rifapentin. J Int AIDS Soc. 2012;15:43.

FDA. KALETRA®, 2010. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021226s030lbl. Accessed on 02 June 2023.

Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997;44(2):190-4.

Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol. 2003;55(3):381-6.

Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J Antimicrob Chemother. 2014;69(9):2310-8.

WHO. Report of the Guideline Development Group Meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis A review of available evidence. Available at: https://apps.who. int/iris/handle/10665/254712. Accessed on 24 June 2023.